METFORMIN HYDROCHLORIDE tablet

País: Estats Units

Idioma: anglès

Font: NLM (National Library of Medicine)

ingredients actius:

METFORMIN HYDROCHLORIDE (UNII: 786Z46389E) (METFORMIN - UNII:9100L32L2N)

Disponible des:

St. Mary's Medical Park Pharmacy

Designació comuna internacional (DCI):

METFORMIN HYDROCHLORIDE

Composición:

METFORMIN HYDROCHLORIDE 850 mg

Vía de administración:

ORAL

tipo de receta:

PRESCRIPTION DRUG

indicaciones terapéuticas:

Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. Metformin hydrochloride tablets are contraindicated in patients with: - Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dL [males], ≥1.4 mg/dL [females] or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see WARNINGS and PRECAUTIONS ). - Known hypersensitivity to metformin hydrochloride. - Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin.

Resumen del producto:

Metformin Hydrochloride Tablets, USP 850 mg - White to off-white, round, biconvex, film coated tablets debossing "H/103" on one side and plain on the other side. NDC 60760-100-90 BOTTLES OF 90 Storage Store at 20°-25° C (68°-77° F); excursions permitted to 15°-30° C (59°-86° F). [See USP Controlled Room Temperature.] Dispense in tight, light-resistant containers with child-resistant closure. Manufactured for: Heritage Pharmaceuticals Inc. Eatontown, NJ 07724 1.866.901. DRUG(3784) Made in India Iss. 07/17

Estat d'Autorització:

Abbreviated New Drug Application

Fitxa tècnica

METFORMIN HYDROCHLORIDE- METFORMIN HYDROCHLORIDE TABLET
ST. MARY'S MEDICAL PARK PHARMACY
----------
METFORMIN HYDROCHLORIDE TABLETS USP
DESCRIPTION
Metformin Hydrochloride Tablets USP are oral antihyperglycemic drugs
used in the management of
type 2 diabetes. Metformin hydrochloride ( _N,N_
-dimethylimidodicarbonimidic diamide hydrochloride)
is not chemically or pharmacologically related to any other classes of
oral antihyperglycemic agents.
The structural formula is as shown:
Metformin hydrochloride is a white to off-white crystalline compound
with a molecular formula of C
H
N
• HCl and a molecular weight of 165.63. Metformin hydrochloride is
freely soluble in water
and is practically insoluble in acetone, ether, and chloroform. The
pKa of Metformin is 12.4. The pH of
a 1% aqueous solution of Metformin hydrochloride is 6.68.
Metformin hydrochloride tablets _,_ USP contains 500 mg, 850 mg, or
1000 mg of Metformin
hydrochloride. Each tablet contains the inactive ingredients povidone
(K-30), povidone (K-90),
pregelatinized starch, and magnesium stearate. In addition, the
coating for the tablets contains artificial
blackberry flavor, hypromellose, macrogol and titanium dioxide.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Metformin is an antihyperglycemic agent which improves glucose
tolerance in patients with type 2
diabetes, lowering both basal and postprandial plasma glucose. Its
pharmacologic mechanisms of action
are different from other classes of oral antihyperglycemic agents.
Metformin decreases hepatic
glucose production, decreases intestinal absorption of glucose, and
improves insulin sensitivity by
increasing peripheral glucose uptake and utilization. Unlike
sulfonylureas, Metformin does not produce
hypoglycemia in either patients with type 2 diabetes or normal
subjects (except in special
circumstances, see PRECAUTIONS ) and does not cause hyperinsulinemia.
With Metformin therapy,
insulin secretion remains unchanged while fasting insulin levels and
day-long plasma insulin response
may actually decrease.
PHA